andrewdudum

Now live: the first AI care agent from Hims & Hers. Trying to decipher complex lab results can be confusing at best and scary at worst (and more often than not, it can take weeks). We’re cutting through that all-too-common experience and making it simple to understand your full health profile — biomarkers, trends, history, context — and how to improve it. This is what is possible when you apply first principles thinking and a world-class engineering team, led by our CTO Mo Elshenawy, to some of healthcare’s biggest challenges. More to come.

I haven’t been to the doctors in over 7 years So it was a relief to have my $HIMS cancer scan come back clean Thanks @AndrewDudum

@maxmarchione 🤣 dead

Breaking: Superpower is acquiring Hims. Half cash. Half stock.

@Angeles1Lost Mind messing me so I can try and help figure out what’s going on? I’m sorry you’re getting stuck here!

I wish I was having the experience you describe. I just subscribed, got the blood labs and cancer blood test very easily. What's NOT easy is the system to communicate with a provider. I've been going in circles messaging for a simple prescription and not getting a clear answer as to how to get a provider to approve it. It's as frustrating as the old health care system!

Every choice we make at Hims & Hers is in the pursuit of a single goal: help more people feel great. It sounds simple, but our current healthcare industry makes it nearly impossible. It’s why more than 2.5M subscribers depend on us for a new experience. One where they’re treated like a person, instead of a patient. Our Q4 and full year 2025 results are live and they are proof that when you put people at the center of health, more people want to engage. Here’s what to know: - We’re growing. Hers is expected to eclipse $1B in revenue this year. Hims revenue grew nearly 30% year-over-year. We launched 3 new offerings in 3 months. And we're focused on scaling global key markets to expand access to high-quality care, which we believe will help us reach $1B in international annual revenue by 2030. Across new markets and new specialties, our business has never encompassed this many new high-impact verticals with the potential to exceed $100M in annual revenue. - We’re more than any one treatment. Since our founding, people have pigeon-holed us based on specific categories. We’ve been known as a hair loss company. An ED company. Today, some may think of us as a GLP-1 company. The reality is that only a small minority of our subscribers are using a compounded GLP-1 treatment. While the cultural conversation changes over time, our value to customers remains the same. Weight Loss is proof of the power of our model and we believe that power is what defines our platform for millions. - We’re creating a new era of consumer health. We see a future where people benefit from innovations in diagnostics, wearables, and data. Where AI can use that data to define and refine treatments and support clinical guidance. And where verticalized infrastructure more efficiently delivers personalized treatments. The first two pillars – stronger technology and deeper data – are advancing across the industry. We believe that innovation demands the third pillar: a scalable way to make the final step in healthcare more precise and more personal. We’re investing in our capabilities in all three. Change is coming to healthcare. More on the progress we made this year here: investors.hims.com/files/doc_fina… Important info here: news.hims.com/disclaimers/ca…

@ConorNeu Message me

I'm personally invested in a company that can tell you whether you will have a heart attack in the next 12 months. With 86% certainty. From a blood test. Unreal value. They are weak at scaling. Someone please buy this and take it to the masses.

Delivering on our ambitious goals requires us to have a strong, multi-disciplinary board that has not only the expertise, but the passion, to help us reimagine everyday health. Kofi Amoo-Gottfried has both, and I’m so excited to be announcing his nomination for election to our board. With decades of experience as a storyteller and brand builder, he has served as the architect for global brands that have redefined everything from human connection to home delivery. news.hims.com/newsroom/hims-…

Given the immense interest in peptides and divergent views about peptides of various types, I assembled a small collection of experts that I’ll be talking to (separately) on the podcast. No matter what your stance is on peptides, it’s wise get educated! They are definitely here to stay!

Love this @buzzfeed conversation with @dankenger. Brilliant design has the ability to power deeper connections with our customers, so it’s at the center of everything we do. An experience that people can trust and actually enjoy transforms health. Our in-house creative team is showing the world what’s possible when you bring that to millions. 🚀✨ buzzfeed.com/business-news/…

As of this morning, providers on our platform can now send prescriptions for Zepbound® vials and KwikPen®, as well as Foundayo™, to the LillyDirect® pharmacy and access self-pay pricing for our customers because of an expansion in our platform’s functionality. In many ways, today reminds me of Netflix’s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix’s success depended on its ability to become the distribution channel for a single film. They were missing the forest for the trees: Netflix wasn’t just renting DVDs. It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most. By offering a full range of FDA-approved GLP-1s on our platform, we’re similarly giving our customers more choices through all the tools we have available – and we’ll continue to push here on behalf of everyone who depends on us for their care. Read more on how we’re making this possible, including important info, here: news.hims.com/newsroom/full-…

Women’s health shouldn’t be on backorder. The national estrogen patch shortage is a systemic failure, but at Hers, we refuse to let women be an afterthought. We’ve built a reliable supply to help ensure they can access the uninterrupted, personalized menopause care women deserve. More here from @JShepherd_MD, Chief Medical Officer of Hers: news.hims.com/newsroom/navig…

Today, the FDA moved towards bringing regulatory clarity on peptide therapy. At Hims & Hers, we believe innovation in longevity care must be guided by safety, transparency, and clinical excellence. Read our statement from Dr. Pat Carroll: news.hims.com/newsroom/appla…

Almost two weeks ago, we kicked off our strategic shift in our weight loss business and shipped our first @novonordisk medicines. We believe we’re on track to deliver more than 100K prescriptions for Wegovy products every month. More treatment options mean more customers can find what works best for them. Helping people get – and stay – healthy is why we’re here. Important Info: news.hims.com/disclaimers/di…

AI can and should change the speed of innovation. We’re now entering an era where you can build a profitable company with a few humans and a lot of AI tools. But in healthcare, innovation means facilitating more real patient-provider relationships and expanding access to actionable health information. It means using AI to help scale access to high-quality, specialty care for more people. Our CTO Mo is building this in real time – more on his team’s progress below. Customers don’t care how much revenue you made last year. They care how safe they are, how much easier you make their life, and how you help them achieve their health goals. There is no substitute for clinical expertise. @tristanharris says that the best version of AI is one that is specifically focused on enhancing a pro-human future. I agree. Speed, growth, and a high valuation mean nothing if your customers can’t trust you or are exposed to risk from the moment they start a relationship with you. “Hyper-efficient” shouldn’t become code for “cutting corners.” Nothing justifies gambling with real people’s lives. When you focus on helping people get healthy, not just getting them through the door, the rest follows. news.hims.com/newsroom/build…

I love days like today because it’s when we get to show how efficiently we can help our customers connect with a provider, find the treatment that is right for them, and get it in their hands. Our first @novonordisk product shipments are heading to homes now! Big thanks to our talented team in Arizona who got the first one out the door this afternoon.

Customer access should move at the same speed as innovation. When the healthcare industry works together to reach individuals, it does. Since last week, thousands of people have signed up for our Wegovy® waitlist. Starting today, eligible Hims & Hers customers can start their journeys with @novonordisk’s FDA-approved Wegovy® Pill & Wegovy® Pen and partner with their provider on a comprehensive weight loss program designed to help them achieve their goals. We take our role as the largest global consumer health platform seriously, and I can’t wait to keep finding ways to make sure everyone can access the tools they need to feel great. Read more below from Dr. Craig, our Head of Weight Loss, on what’s available today. (And if you’re starting your Wegovy journey with us today, tag me and tell me how it’s going!) More details, including important info, here: news.hims.com/newsroom/wegov…

@chrisrudy @Lajartinho @icyops @rihadrr legend. thank you for the hustle 🙏

Day 100/100 of making an ad for $HIMS until @AndrewDudum hires me or $HIMS goes to $100 Unfortunately... neither happened. Such is the nature of life. The most important thing is that you show up every day and give it your best. Thank you @Lajartinho, @icyops, @rihadrr, @EverardEoin, @JerBearRN, @galligator, @arabrodeo, @InvestingDoc, @RobbyWade6, @davesoderberg, @AbolishAging, @mattscottcap, @dullyyyy, @baroqueboi1, @yveysopiqoti, @newmanjr, @yourenotmartin,@DrCamRx, @Keithdavis85, @Rational_User, @DamianW98930911, @NighthawkTradez, @alc2022, @Stayka_POPCAT, @valaorh, @MarcalCarbo, @Davidrejll, @daveshiacc and many many others who were there holding bags with me when the going got tough. I appreciate all of you. Thank you. $HIMS to $100! 👀

A very large number of people trust credentialed MDs but *also* self elected blood work & exercise & nutrition adjusted to one’s needs & supplements & many are peptide curious too (not just GLPs). Any post or article about these camps being at odds = out of touch w/the majority.

A new era of weight management is coming to Hims & Hers. Soon: access to FDA-approved GLP-1 treatments — including Wegovy® pills and injections. Join our exclusive pre-launch waitlist today: bit.ly/4cOLcQV 𝘞𝘦𝘨𝘰𝘷𝘺® 𝘪𝘴 𝘢 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬 𝘰𝘧 𝘕𝘰𝘷𝘰 𝘕𝘰𝘳𝘥𝘪𝘴𝘬 𝘈/𝘚.

@alc2022 Already built into Labs!

@AndrewDudum When does $Hims drop a lipoprotein alpha protocol

This has taken years to trickle through the system! A huge advancement in getting proactive with heart disease, one of our most preventable diseases. Huge win that will save many lives!

Booked my first lab appointment today w/ $HIMS Thank you @AndrewDudum for providing people the tools needed to healthmax $349/year is less than $1 a day $HIMS @HimsHersComms @wearehims @himshouse